Literature DB >> 1930310

The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy.

M Dougados1, S van der Linden, R Juhlin, B Huitfeldt, B Amor, A Calin, A Cats, B Dijkmans, I Olivieri, G Pasero.   

Abstract

Classification criteria for most of the disorders belonging to the spondylarthropathy group already exist. However, the spectrum of spondylarthropathy is wider than the sum of these disorders suggests. Seronegative oligoarthritis, dactylitis or polyarthritis of the lower extremities, heel pain due to enthesitis, and other undifferentiated cases of spondylarthropathy have been ignored in epidemiologic studies because of the inadequacy of existing criteria. In order to define classification criteria that also encompass patients with undifferentiated spondylarthropathy, we studied 403 patients with all forms of spondylarthropathy and 674 control patients with other rheumatic diseases. The diagnoses were based on the local clinical expert's opinion. The 403 patients included 168 with ankylosing spondylitis, 68 with psoriatic arthritis, 41 with reactive arthritis, 17 with inflammatory bowel disease and arthritis, and 109 with unclassified spondylarthropathy. Based on statistical analysis and clinical reasoning, we propose the following classification criteria for spondylarthropathy: inflammatory spinal pain or synovitis (asymmetric or predominantly in the lower limbs), together with at least 1 of the following: positive family history, psoriasis, inflammatory bowel disease, urethritis, or acute diarrhea, alternating buttock pain, enthesopathy, or sacroiliitis as determined from radiography of the pelvic region. These criteria resulted in a sensitivity of 87% and a specificity of 87%. The proposed classification criteria are easy to apply in clinical practice and performed well in all 7 participating centers. However, we regard them as preliminary until they have been further evaluated in other settings.

Entities:  

Mesh:

Year:  1991        PMID: 1930310     DOI: 10.1002/art.1780341003

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  529 in total

1.  Flow cytometric analysis of gut mucosal lymphocytes supports an impaired Th1 cytokine profile in spondyloarthropathy.

Authors:  N Van Damme; M De Vos; D Baeten; P Demetter; H Mielants; G Verbruggen; C Cuvelier; E M Veys; F De Keyser
Journal:  Ann Rheum Dis       Date:  2001-05       Impact factor: 19.103

2.  Parovirus B19-associated mono- and oligoarticular arthritis may evolve into a chronic inflammatory arthropathy fulfilling criteria for rheumatoid arthritis or spondylarthropathy.

Authors:  H D Stahl; R Pfeiffer; G Von Salis-Soglio; F Emmrich
Journal:  Clin Rheumatol       Date:  2000       Impact factor: 2.980

Review 3.  Spondylarthropathies: options for combination therapy.

Authors:  A M van Tubergen; R B Landewé; S van der Linden
Journal:  Springer Semin Immunopathol       Date:  2001

4.  Reactive arthritis in Brazil.

Authors:  E S Meirelles; E M Pastor; D P de-Oliveira; M A de-Oliveira; T Rosales
Journal:  Clin Rheumatol       Date:  2001       Impact factor: 2.980

5.  Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up.

Authors:  E Kruithof; F Van den Bosch; D Baeten; A Herssens; F De Keyser; H Mielants; E M Veys
Journal:  Ann Rheum Dis       Date:  2002-03       Impact factor: 19.103

Review 6.  Treatment of active spondyloarthropathy with infliximab, the chimeric monoclonal antibody to tumour necrosis factor alpha.

Authors:  F Van den Bosch; D Baeten; E Kruithof; F De Keyser; H Mielants; E M Veys
Journal:  Ann Rheum Dis       Date:  2001-11       Impact factor: 19.103

Review 7.  Ankylosing spondylitis: introductory comments on its diagnosis and treatment.

Authors:  M A Khan
Journal:  Ann Rheum Dis       Date:  2002-12       Impact factor: 19.103

Review 8.  'MRI-tis' in the early diagnosis of axial SpA: issues and limitations.

Authors:  Leen De Rycke; Mario Maas; Paul P Tak; Dominique Baeten
Journal:  Nat Rev Rheumatol       Date:  2010-10-05       Impact factor: 20.543

9.  Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study.

Authors:  F Van den Bosch; E Kruithof; D Baeten; F De Keyser; H Mielants; E M Veys
Journal:  Ann Rheum Dis       Date:  2000-06       Impact factor: 19.103

10.  Subclinical sacroiliitis in brucellosis. Clinical presentation and MRI findings.

Authors:  T A Gheita; S Sayed; G S Azkalany; H S El Fishawy; M A Aboul-Ezz; M H Shaaban; R H Bassyouni
Journal:  Z Rheumatol       Date:  2015-04       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.